A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02).

Trial Profile

A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PaZ02
  • Most Recent Events

    • 28 Jan 2016 Planned End Date changed from 31 Dec 2015 to 31 Aug 2016, according to United Kingdom Clinical Research Network record
    • 28 Jan 2016 Accural to date is 82% according to United Kingdom Clinical Research Network
    • 04 Dec 2015 Accrual to date is 80% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top